Deal to progress Alzheimer's vaccine

AFFiRiS GmbH has granted GlaxoSmithKline Biologicals S.A. (GSK) exclusive rights to develop and commercialise its Alzheimer's disease vaccine candidates. Two are currently in Phase I clinical development, and others are in preclinical development.

The AFFiRiS AFFiTOPE technology allows the design of proteins with very specific binding characteristics that are ideally suited for the development of vaccines against disease-causing ‘rogue’ human proteins, such as beta-amyloid – central to Alzheimer’s disease pathology.
AFFiRiS GmbH (www.affiris.com) develops peptide-based vaccines to combat Alzheimer’s disease, atherosclerosis and other diseases. The company has established platform technologies and a worldwide patent portfolio covering their vaccine candidates.

20.11.2008

News • Immunoassay limitations

Sickle cell trait could throw off diabetes test, study finds

A common diabetes test could miss the condition in people with sickle cell trait, new research suggests. Understanding this limitation of immunoassay testing could help guide protocols and policies.

News • Elevated urea levels

Does ‘toxic waste’ build-up in the brain drive dementia and ALS?

In a study, researchers found unusually high levels of urea in the brains of people with frontotemporal dementia and ALS. The findings raise questions about how the brain clears harmful substances.

News • Stain-Free Histology

Nanophotonic slides add color to tissue samples

Researchers have developed a method to enhance the cellular features in pathology slides based on “structural color” – the same effect that gives peacock feathers their unique sheen.

Related articles